Trade Alert: The Founder Of Clover Biopharmaceuticals, Ltd. (HKG:2197), Peng Liang, Has Just Spent CN¥1.0m Buying A Few More Shares
Potential Clover Biopharmaceuticals, Ltd. (HKG:2197) shareholders may wish to note that the Founder, Peng Liang, recently bought HK$1.0m worth of stock, paying HK$3.63 for each share. Although the
Clover Bio Raises HK$501 Million From Share Placement
07:07 AM EST, 12/13/2022 (MT Newswires) -- Clover Biopharmaceuticals (HKG:2197) raised HK$500.5 million from its recently concluded private placement of 128 million shares, according to a Tuesday disc
Clover Biopharmaceuticals to Place Shares
08:40 PM EST, 12/05/2022 (MT Newswires) -- Clover Biopharmaceuticals (HKG:2197) is placing 128 million shares, raising an estimated HK$500.5 million in net proceeds, according to a Tuesday filing. The
Clover Biopharmaceuticals, Ltd.'s (HKG:2197) Market Cap Surged HK$2.7b Last Week, Individual Investors Who Have a Lot Riding on the Company Were Rewarded
Every investor in Clover Biopharmaceuticals, Ltd. (HKG:2197) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are individual investors wi
Founder Peng Liang Just Bought A Handful Of Shares In Clover Biopharmaceuticals, Ltd. (HKG:2197)
Whilst it may not be a huge deal, we thought it was good to see that the Clover Biopharmaceuticals, Ltd. (HKG:2197) Founder, Peng Liang, recently bought HK$549k worth of stock, for HK$1.83 per share.
Is Clover Biopharmaceuticals (HKG:2197) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares
Mid-term report of clover organism-Bazu 2022
Biden Signs Order to Curb China in Biotechnology Following Chip Bill
The US government is reported to introduce new regulations next month to prohibit American companies from exporting chipmaking equipment to Chinese factories that produce advanced semiconductors with sub-14 nanometer processes.
Clover Biopharmaceuticals' COVID-19 Vaccine Candidate Neutralizes Certain Virus Strains in Phase 3 Trial
10:42 PM EDT, 09/05/2022 (MT Newswires) -- Clover Biopharmaceuticals' (HKG:2197) SCB-2019 COVID-19 vaccine candidate neutralized antibodies against the original strain of the virus and two Omicron sub
Clover Biopharmaceuticals' COVID-19 Booster Candidate Neutralizes Omicron Subvariant During Trial
10:55 PM EDT, 08/29/2022 (MT Newswires) -- Clover Biopharmaceuticals' (HKG:2197) COVID-19 booster shot candidate SCB-2019 neutralized the omicron BA.5 subvariant during a phase 2/3 clinical trial, a T
No Stock Yet